Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Plasma Concentrations Clear all
Completed No phase listed Observational

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

NCT00177827
View directory record Official record
Conditions
Post Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 21, 2026, 10:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Uterine Infusion

NCT06621342
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
PRP Experimental
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
23 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Measurement of Plasma and Intracellular Concentrations of Raltegravir

NCT01214486
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

NCT01691274
View directory record Official record
Conditions
Healthy
Interventions
PF-04895162, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 21, 2026, 10:58 PM EDT
Completed No phase listed Observational

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 21, 2026, 10:58 PM EDT
Completed No phase listed Observational

Genetic Influences on Statin Blood Concentrations in African Americans

NCT01569867
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Processed Orange and the Glycemic Response

NCT02112851
View directory record Official record
Conditions
Maximum Observed Plasma Glucose Concentration (Cmax)
Interventions
Orange flavored beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 21, 2026, 10:58 PM EDT
Completed No phase listed Observational

Voriconazole Blood Levels and Toxicity

NCT00359541
View directory record Official record
Conditions
Pharmacology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:58 PM EDT
Terminated Phase 1 Interventional

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

NCT03277209
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Plerixafor
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects

NCT02453529
View directory record Official record
Conditions
Healthy
Interventions
WCK 4873
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma and Intrapulmonary Concentrations Study of WCK 5222

NCT03630094
View directory record Official record
Conditions
PHA1A
Interventions
FEP-ZID
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 21, 2026, 10:58 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

NCT03137017
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05283915
View directory record Official record
Conditions
Hepatic Function Abnormal
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 10:58 PM EDT
Completed No phase listed Observational Results available

Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections

NCT01200875
View directory record Official record
Conditions
Tendinopathy, Rheumatic Diseases
Interventions
Ultrasound-guided platelet-rich-plasma (PRP) injection, Platelet-Rich Plasma (PRP)
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy

NCT05373615
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Cefiderocol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

NCT02001688
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Kamada-AAT for Inhalation, 80mg, Placebo, Kamada-AAT for Inhalation, 160mg
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 21, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

NCT02267317
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 10:58 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 21, 2026, 10:58 PM EDT
Terminated No phase listed Observational

Plasma Concentration of Biological Markers in Placental Abruption

NCT03782168
View directory record Official record
Conditions
Abruptio Placentae
Interventions
There is no other intervention, only clinical treatment.
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population

NCT04298099
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Ropivacaine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Months to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 21, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076
View directory record Official record
Conditions
Nonhematologic Malignancies, Lymphoma
Interventions
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 21, 2026, 10:58 PM EDT